FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer By Ogkologos - January 7, 2026 257 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AMPLITUDE study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Front-line CS1001 Plus Platinum-Based Chemotherapy Delivers Substantial Benefit in Advanced Non-Small... November 21, 2020 Kinder and more effective – why childhood cancers need specific treatments September 3, 2021 ESMO Breast Cancer 2024, 15-17 May, Berlin, Germany May 8, 2024 Results of Pivotal Study with BCMA Specific CAR T-Cell Therapy in... March 3, 2021 Load more HOT NEWS How Do Black People with Cancer View Clinical Research? ASCO 2023 roundup: Blood tests, drugs and exercise European Lung Cancer Congress 2025, Paris, France, 26-29 March 2025 Promising Activity of Patritumab Deruxtecan in Patients with HR-positive, HER2-negative MBC...
